Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Inks $500M Subscription Agreement to Fund Life Tech Purchase

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today said that it has entered into a subscription agreement to raise $500 million in gross proceeds to help fund its purchase of Life Technologies.

Under the terms of the agreement, which Thermo Fisher disclosed in a document filed with the US Securities and Exchange Commission, the company will issue in a private placement up to approximately 5.3 million shares of its common stock to Temasek at $95 per share. The share price will be adjusted depending on when the investment closes.

Temasek is a government-owned investment firm based in Singapore.

Thermo Fisher said it does not expect to sell any more equity or equity-linked securities to fund the $13.6 billion acquisition of Life Tech, expected to be completed in early 2014. It previously raised $2.2 billion in a public offering of its shares and entered into a bridge credit agreement and term loan agreement totaling $12.5 billion in order to finance the deal.

In Friday morning trade on the New York Stock Exchange, shares of Thermo Fisher were up 1 percent at $101.18.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.